Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.00
-0.10 (-0.40%)
Jan 21, 2026, 1:21 PM CST
-9.42%
Market Cap2.41B
Revenue (ttm)184.91M
Net Income (ttm)-70.14M
Shares Out95.95M
EPS (ttm)-0.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,154
Average Volume143,458
Open25.10
Previous Close25.10
Day's Range24.35 - 25.10
52-Week Range19.80 - 33.65
Beta0.23
RSI38.77
Earnings DateApr 24, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company’s products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 34
Stock Exchange Taipei Exchange
Ticker Symbol 6704
Full Company Profile

Financial Performance

In 2024, TPEX:6704's revenue was 170.03 million, an increase of 20.44% compared to the previous year's 141.18 million. Losses were -83.32 million, -5.41% less than in 2023.

Financial Statements